You hit the nail on the head Bob, Oncosec couldn't afford to go ahead with the combinational pd1 trial until a pd1 was approved. Now things are really getting interesting with this approval, and who was that Doctor that was in charge of a 20 member research team for Merck's pd1 drug. Shareholders who were run off in the .40s and now selling in the .50s will probably be regretting it possibly very soon.
News 
Market Data 
Discover 
AI
